NO20054914L - Forbindelse med affinitet til kalsifisert vev - Google Patents

Forbindelse med affinitet til kalsifisert vev

Info

Publication number
NO20054914L
NO20054914L NO20054914A NO20054914A NO20054914L NO 20054914 L NO20054914 L NO 20054914L NO 20054914 A NO20054914 A NO 20054914A NO 20054914 A NO20054914 A NO 20054914A NO 20054914 L NO20054914 L NO 20054914L
Authority
NO
Norway
Prior art keywords
compound
calcified tissue
affinity
group
integer
Prior art date
Application number
NO20054914A
Other languages
English (en)
Norwegian (no)
Inventor
Osamu Itoh
Nobuhiko Kanazashi
Aki Morishita
Miki Kurami
Original Assignee
Nihon Mediphysics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nihon Mediphysics Co Ltd filed Critical Nihon Mediphysics Co Ltd
Publication of NO20054914L publication Critical patent/NO20054914L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO20054914A 2003-03-26 2005-10-24 Forbindelse med affinitet til kalsifisert vev NO20054914L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003085919 2003-03-26
PCT/JP2004/004019 WO2004085452A1 (ja) 2003-03-26 2004-03-24 石灰化組織親和性化合物

Publications (1)

Publication Number Publication Date
NO20054914L true NO20054914L (no) 2005-11-03

Family

ID=33095045

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054914A NO20054914L (no) 2003-03-26 2005-10-24 Forbindelse med affinitet til kalsifisert vev

Country Status (11)

Country Link
US (1) US20060189567A1 (zh)
EP (1) EP1609797A1 (zh)
JP (1) JP4723378B2 (zh)
KR (1) KR20050109608A (zh)
CN (1) CN1764670A (zh)
AU (1) AU2004223955A1 (zh)
BR (1) BRPI0408717A (zh)
CA (1) CA2520147A1 (zh)
NO (1) NO20054914L (zh)
TW (1) TW200505934A (zh)
WO (1) WO2004085452A1 (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9820986B2 (en) 2005-03-04 2017-11-21 Taiwan Hopaz Chems, Mfg. Co., Ltd. Glycopeptide compositions
JP2008266194A (ja) * 2007-04-19 2008-11-06 Hiroshi Tanaka 分子プローブの原料として有用な新規有機化合物
CN107326674A (zh) * 2017-07-21 2017-11-07 安徽华锦柏亚纤纺科技有限公司 一种涤棉梭织物的防水防油整理方法
CN108872131A (zh) * 2018-08-16 2018-11-23 浙江诚意药业股份有限公司 一种鉴别甲壳类氨基葡萄糖和微生物法氨基葡萄糖的方法
JP2022547638A (ja) * 2019-09-03 2022-11-14 プロサイプラ セラピューティクス， エルエルシー 新規の多形およびその使用
KR20210031159A (ko) * 2019-09-11 2021-03-19 주식회사 엘지화학 리튬 이차전지용 비수전해액 및 이를 포함하는 리튬 이차전지
CN114652852A (zh) * 2020-12-22 2022-06-24 浙江大学 诱导肿瘤细胞发生自发钙化的分子及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5750928A (en) * 1980-09-13 1982-03-25 Nippon Mejifuijitsukusu Kk Diagnostic agent for scanning bone
GB8310438D0 (en) * 1983-04-18 1983-05-25 Amersham Int Plc Bone-seeking complexes of technetium-99m
JP2815615B2 (ja) * 1988-06-07 1998-10-27 日本メジフィジックス株式会社 ジエチレントリアミン五酢酸誘導体とその用途
US5094950A (en) * 1988-06-07 1992-03-10 Nihon Medi-Physics Co., Ltd. Diethylenetriamine pentaacetic acid derivatives
US5250702A (en) * 1988-06-07 1993-10-05 Nihon Medi-Physics Co., Ltd. Diethylenetriamine pentaacetic acid derivatives
US5089249A (en) * 1988-06-10 1992-02-18 Neorx Corporation Conjugates for bone imaging and bone cancer therapy
US5202109A (en) * 1988-06-10 1993-04-13 Neorx Corporation Conjugates for bone imaging and bone cancer therapy
JP3048628B2 (ja) * 1990-11-30 2000-06-05 イハラケミカル工業株式会社 還元ヘキサ―ｎ―アセチル―キトヘキサオースを有効成分とする抗腫瘍剤
JPH07206895A (ja) * 1993-10-22 1995-08-08 Nippon Mejifuijitsukusu Kk 炎症親和性ペプチド及び該ペプチドを含有してなる放射性診断剤
AU675166B2 (en) * 1993-10-22 1997-01-23 Nihon Medi-Physics Co., Ltd. Peptide having inflammation affinity and radioactive diagnostic containing the same
JP2001114792A (ja) * 1999-10-12 2001-04-24 Nihon Medi Physics Co Ltd ビスホスホン酸誘導体およびその放射性核種標識体
JP4185273B2 (ja) * 2000-10-11 2008-11-26 日本メジフィジックス株式会社 アミド化合物の製造方法
IL145723A0 (en) * 2000-10-11 2002-07-25 Nihon Mediphysics Co Ltd Process for producing an amide compound

Also Published As

Publication number Publication date
US20060189567A1 (en) 2006-08-24
TW200505934A (en) 2005-02-16
EP1609797A1 (en) 2005-12-28
CN1764670A (zh) 2006-04-26
KR20050109608A (ko) 2005-11-21
CA2520147A1 (en) 2004-10-07
JP4723378B2 (ja) 2011-07-13
WO2004085452A1 (ja) 2004-10-07
BRPI0408717A (pt) 2006-03-07
AU2004223955A1 (en) 2004-10-07
JPWO2004085452A1 (ja) 2006-06-29

Similar Documents

Publication Publication Date Title
NO20054914L (no) Forbindelse med affinitet til kalsifisert vev
HK1083414A1 (en) Method for monitoring blood flow and metabolic uptake in tissue with radiolabeled alkanoic acid
BRPI0608376A8 (pt) composição de ligação, método de uso de uma composição de ligação, e, kit de detecção
WO2004042346A3 (en) Methods and compositions for diagnosing and monitoring transplant rejection
WO2005113831A3 (en) Biomarkers for multiple sclerosis and methods of use thereof
DK1651615T3 (da) Pyridazinyl-piperaziner og anvendelse deraf som histamin-H3-receptorligander
NO20054220L (no) Substituerte N-arylheterocykler, fremgangsmate for fremstilling derav og deres anvendelse som legemiddel
NO20061766L (no) 1,1,1-trifluor-4-fenyl-4-metyl-2-(1H-Pyrrolo'2,3-Cl Pyridin-2-ylmetyl)pentan-2-ol derivater og beslektede forbindelser som glukokortikoidligander for behandling av inflammatoriske sykdommer og diabetes
NZ520071A (en) 4-aminopiperidine derivatives and their use as medicine
WO2003024928A3 (en) Novel aminoazetidine, -pyrrolidine and -piperidine derivatives
WO2007139815A3 (en) Imaging and therapeutic method using progenitor cells
GB2436996B8 (en) Rigid amines
WO2007031878A3 (en) Methods of treating nervous disorders
WO2005077462A3 (en) Cd70 inhibition for the treatment and prevention of inflammatory bowel disease
PT2332582E (pt) Activação de ace2 para o tratamento de doença cardíaca, pulmonar e renal e de hipertensão
WO2007119001A3 (fr) Derives d 'aminomethyl pyridine, leur preparation et leur application en therapeutique
WO2005123077A8 (en) Heteroaryl sulfones and sulfonamides and therapeutic uses thereof
EP1482361A4 (en) ACID-DEGRADABLE RESIN COMPOSITIONS BASED ON CETENE-ALDEHYDE COPOLYMER
WO2003087760A3 (en) Methods for detecting bcr-abl signaling activity in tissues using phospho- specific antibodies
WO2008011484A3 (en) Nicotinic desensitizers and methods of selecting, testing, and using them
DE502004005226D1 (de) Diagnosestellung von akuten myokardialen, ischämischen erkrankungen durch kombination von markern
MXPA05011895A (es) Composiciones para lipidos inferiores en el cuerpo.
NO20063295L (no) Naert-infrarodt, fluorescerende kontrastmiddel
WO2004092706A3 (en) Control bracketing and results hold for immunoanalyzer
JP2005525325A5 (zh)